Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498842 | 1.00 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL1316928 | 1.00 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL4307712 | 1.00 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL1317329 | 1.00 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL1316405 | 1.00 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL11512674 | 0.98 | CES1 (0.53) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL2313583 | 0.98 | CES1 (0.53) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL13814881 | 0.98 | CES1 (0.52) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL8975703 | 0.96 | CES1 (0.52) | CES1HTTMEN1KMT2ATHRB | |
| SCHEMBL2018151 | 0.96 | CES1 (0.55) | CES1HTTMEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6077896-A | COMPOSITION COMPRISING OXYALKYLENE POLYMER CONTAINING REACTIVE SILYL GROUPS, COMPOUND HAVING INTRAMOLECULAR ALPHA, BETA-DIOL OR ALPHA, GAMMA-DIOL STRUCTURE | KANEKA CORPORATION (JP) | 2000-06-20 | — | — | US | claimed |
| EP-2759581-B1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORP (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-9593271-B2 | Curable composition and cured product thereof | KANEKA CORPORATION (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20140288222-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORPORATION (JP) | 2014-09-25 | — | — | US | disclosed |
| EP-2759581-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | Kaneka Corporation (JP) | 2014-07-30 | — | — | EP | disclosed |
| EP-1731549-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20110269652-A1 | GEMINI SURFACTANTS | ST. FRANCIS XAVIER UNIVERSITY (CA) | 2011-11-03 | — | — | US | disclosed |
| EP-2349978-A1 | GEMINI SURFACTANTS | St. Francis Xavier University (CA) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048715-A1 | GEMINI SURFACTANTS | ST. FRANCIS XAVIER UNIVERSITY (CA) | 2010-05-06 | — | — | WO | disclosed |
| US-20090234072-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1923431-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-05-21 | — | — | EP | disclosed |
| US-20080051517-A1 | Curable Composition | KANEKA CORPORATION | 2008-02-28 | — | — | US | disclosed |
| EP-1852472-A1 | CURABLE COMPOSITION AND CURED OBJECT THEREOF | Kaneka Corporation (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1731549-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1731544-A1 | HARDENABLE COMPOSITION | KANEKA CORPORATION (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-20060135709-A1 | Curing composition | KANEKA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1637565-A1 | CURING COMPOSITION | KANEKA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-0902042-B1 | Curable composition | KANEKA CORP (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6077896-A | COMPOSITION COMPRISING OXYALKYLENE POLYMER CONTAINING REACTIVE SILYL GROUPS, COMPOUND HAVING INTRAMOLECULAR ALPHA, BETA-DIOL OR ALPHA, GAMMA-DIOL STRUCTURE | KANEKA CORPORATION (JP) | 2000-06-20 | — | — | US | disclosed |
| EP-0902042-A1 | Curable composition | Kaneka Corporation (JP) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269652-A1 | GEMINI SURFACTANTS | SGMS1, DEGS1, GMNN | CES1 103/4885HTT 1291/4885MEN1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.